Citius Oncology Signs US Distribution Deal With McKesson for Lymphir
MT Newswires Live
Oct 20
Citius Oncology (CTOR) said Monday it has signed an agreement naming McKesson (MCK) as an authorized US distributor of Lymphir, an immunotherapy for adults with relapsed or refractory stage I to III cutaneous T-cell lymphoma.
Financial details were not provided.
McKesson joins two other distributors, completing the core US distribution network for Lymphir, Citius said.
Lymphir has been approved by the US Food and Drug Administration, with a commercial launch planned for Q4, according to the company.
Citius shares were up more than 5% in early trading Monday, and McKesson stock was slightly higher.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.